RxDoctor Payments Data

Adrian Lombardi, MD

Family Medicine · Bay Shore, NYNPI 1861623472

Payments from drug & device makers

$487in general payments, 2019–2025

Across 17 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$161
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$99
  • Merck$45
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42
  • Boston Scientific$31
  • Pfizer$27
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$162,356
Medicare patients
346
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$59,668
JanuviaSitagliptin Phosphate41$41,422
OzempicSemaglutide20$25,014
FarxigaDapagliflozin Propanediol19$17,854
EntrestoSacubitril/Valsartan16$17,207
XareltoRivaroxaban18$16,238
JardianceEmpagliflozin14$14,503
TradjentaLinagliptin13$13,615
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$9,446
Levothyroxine Sodium347$4,234
Metoprolol Succinate198$3,271
Albuterol Sulfate HfaAlbuterol Sulfate131$3,024
Rosuvastatin Calcium282$2,609
SynthroidLevothyroxine Sodium47$2,134
Ibandronate Sodium64$2,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$59,66853 claims
MerckJanuvia$45$41,42241 claims
AstraZenecaFarxiga$161$17,85419 claims
Johnson & JohnsonXarelto$14$16,23818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →